The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
By R. Alaggio, Catalina Amador, I. Anagnostopoulos, A. Attygalle, I. Araújo, E. Berti, G. Bhagat, A. Borges, Daniel Boyer, M. Calaminici and 73 more. Leukemia, 2022
3,276 citations recorded by the source corpus.
We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.
Subfields: Genetics, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/e1e45faa3edf0e1cb0f6ca7fae58353f4a2e9061
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022, background): “Indeed, neoplasms that arise from lymphoid stromal cells such as follicular dendritic cell sarcoma and fibroblastic reticular cell tumor are now appropriately classified under the new chapter of “stroma-derived neoplasms of lymphoid tissues” as detailed in the companion manuscript [4].”